These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1942932)

  • 41. Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children.
    Kremer LC; Tiel-van Buul MM; Ubbink MC; Offringa M; Ottenkamp J; Olmos RV; Voûte PA
    J Clin Oncol; 1999 Apr; 17(4):1208. PubMed ID: 10561180
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pharmacokinetics and acute signs of cardiac toxicity during doxorubicin therapy].
    Lenzhofer R; Schneeweiss B; Rameis H; Eichler H; Graninger W; Dittrich C; Dudczak R; Ganzinger U; Gasic S; Moser K
    Wien Klin Wochenschr; 1983 Jan; 95(2):52-5. PubMed ID: 6858169
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Late effects of anthracycline therapy in childhood on signal-averaged ECG parameters.
    Mladosievicova B; Foltinova A; Petrasova H; Hulin I
    Int J Mol Med; 2000 Apr; 5(4):411-4. PubMed ID: 10719059
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low R-wave amplitude in the right precordial leads in children with symptomatic doxorubicin cardiomyopathy.
    Umemoto M; Azuma E; Itoh M; Komada Y; Ido M; Kawasaki H; Kita H; Sakurai M
    Pediatr Cardiol; 1993 Mar; 14(2):107-9. PubMed ID: 8385775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
    Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
    Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mitral regurgitation after anthracycline treatment for childhood malignancy.
    Allen J; Thomson JD; Lewis IJ; Gibbs JL
    Heart; 2001 Apr; 85(4):430-2. PubMed ID: 11250971
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Changes in myocardial function in patients with acute leukemias under the influence of rubomycin].
    Bessmel'tsev SS; Abdulkadyrov KM
    Ter Arkh; 1994; 66(11):80-4. PubMed ID: 7900029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
    Steinherz LJ; Steinherz PG; Tan CT; Heller G; Murphy ML
    JAMA; 1991 Sep; 266(12):1672-7. PubMed ID: 1886191
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer.
    Tikanoja T; Riikonen P; Perkkiö M; Helenius T
    Med Pediatr Oncol; 1998 Aug; 31(2):73-8. PubMed ID: 9680930
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Can comprehensive echocardiographic evaluation provide an advantage to predict anthracycline-induced cardiomyopathy?
    Erdoğan D; Yücel H; Alanoğlu EG; Uysal BA; Koçer M; Ozaydın M; Doğan A
    Turk Kardiyol Dern Ars; 2011 Dec; 39(8):646-53. PubMed ID: 22257802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Daunomycin-and adriamycin-induced cardiomyopathy--relationship between dosage of drugs and histopathological findings (author's transl)].
    Yamaguchi H; Toyota S; Takahara O; Ichimaru M
    Rinsho Ketsueki; 1978 Aug; 19(8):1041-50. PubMed ID: 713049
    [No Abstract]   [Full Text] [Related]  

  • 52. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.
    van Dalen EC; van der Pal HJ; Kok WE; Caron HN; Kremer LC
    Eur J Cancer; 2006 Dec; 42(18):3191-8. PubMed ID: 16987655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
    Grenader T; Goldberg A; Gabizon A
    Anticancer Drugs; 2010 Oct; 21(9):868-71. PubMed ID: 20679886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nutritional status and anthracycline cardiotoxicity in children.
    Obama M; Cangir A; van Eys J
    South Med J; 1983 May; 76(5):577-8. PubMed ID: 6573781
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The effect of the anthracycline derivative doxorubicin on myocardial function in children].
    Sobotka-Plojhar MA; Daniëls O; Rohmer J; Veerman AJ; Lippens R; van Lier H
    Ned Tijdschr Geneeskd; 1989 Jul; 133(27):1367-70. PubMed ID: 2797225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Physical performance in long-term survivors of acute leukaemia in childhood.
    Black P; Gutjahr P; Stopfkuchen H
    Eur J Pediatr; 1998 Jun; 157(6):464-7. PubMed ID: 9667400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study.
    Chow AY; Chin C; Dahl G; Rosenthal DN
    J Clin Oncol; 2006 Feb; 24(6):925-8. PubMed ID: 16484703
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Functional myocardial impairment in children treated with anthracyclines for cancer.
    Yeung ST; Yoong C; Spink J; Galbraith A; Smith PJ
    Lancet; 1991 Apr; 337(8745):816-8. PubMed ID: 1672914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.